CytoMed Therapeutics Ltd. (GDTC) News

CytoMed Therapeutics Ltd. (GDTC): $2.07

0.05 (+2.48%)

POWR Rating

Component Grades

Momentum

NR

Stability

NR

Sentiment

Quality

NR

Add GDTC to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

NR

Ranked

#NR of NR

in industry

Filter GDTC News Items

GDTC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

GDTC News Highlights

  • GDTC's 30 day story count now stands at 2.
  • Over the past 16 days, the trend for GDTC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest GDTC News From Around the Web

Below are the latest news stories about CYTOMED THERAPEUTICS LTD that investors may wish to consider to help them evaluate GDTC as an investment opportunity.

One CytoMed Therapeutics Insider Raised Stake By 46% In Previous Year

From what we can see, insiders were net buyers in CytoMed Therapeutics Limited's ( NASDAQ:GDTC ) during the past 12...

Yahoo | December 21, 2023

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc.,

Yahoo | December 5, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results and provided clinical and corporate updates.

Yahoo | November 17, 2023

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced it will be presenting at The Benchmark Company's 12th Annual Discovery One-on-One Investor Conference to be held Thursday, December 7th, 2023 at the New York Athletic Club in New York City.

Yahoo | November 14, 2023

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies ...

Yahoo | October 24, 2023

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that its exclusively licensed induced pluripotent stem cell (iPSC)-based technology has been granted a patent by the China National Intellectual Property Administration (CNIPA).

Yahoo | September 25, 2023

CytoMed Expands Research Collaboration into China After Entering Into MOU

CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced entering into a Memorandum of Understanding (MOU) with China-based Hangzhou CNK Therapeutics Co., Ltd. (CNK).

Yahoo | August 29, 2023

CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual Investor Summit.Event:August 24th Investor SummitPresentation:August 24, 2023 at 11:00am ETLocation:https://us06web.zoom.us/webinar/register/WN_lq55Oh7vTrGuASU1uYFecg 1x1s will be available for qualified investorsThe conference is completely complimentary to qualified investors. Please register at Co

Yahoo | August 17, 2023

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK). With this agreement, CytoMed can utilize CNK's PiggyBac technology to permanently graft the Chimeric Antigen Receptor (CAR) g

Yahoo | August 15, 2023

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announced that the chimeric antigen receptor gamma delta T cell (CAR-γδ T cell) technology, which is exclusively licensed from the Agency for Science, Technology and Research (A*STAR), has been granted a patent by the China National Intell

Yahoo | August 1, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!